Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
about
Skin patch and vaginal ring versus combined oral contraceptives for contraceptionCombination contraceptives: effects on weightCombination contraceptives: effects on weightSkin patch and vaginal ring versus combined oral contraceptives for contraceptionCombination contraceptives: effects on weightContraceptive failure in the United StatesContraception technology: past, present and futureEffect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic reviewDevelopment of topical microbicides to prevent the sexual transmission of HIVInfluence of structured counseling on women's selection of hormonal contraception in Israel: results of the CHOICE study.Intention to use a combined contraceptive method and decision after counselling in Switzerland--Swiss data from the European CHOICE study.Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).Multicenter Study of Contraceptive Vaginal Ring (NuvaRing(®)) in Normal Daily Practice in Indian Women.Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introductionContraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese womenReview of the combined contraceptive vaginal ring, NuvaRing.A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding.Contraceptive failure related to estimated cycle day of conception relative to the start of the last bleeding episode.The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.Characteristics of women screened for a contraceptive intravaginal ring study in Kisumu, Kenya, 2014Efficacy of combined contraceptive vaginal ring versus oral contraceptive pills in achieving hypothalamic-pituitary-ovarian axis suppression in egg donor in vitro fertilization cycles.New and emerging contraceptives: a state-of-the-art review.Efficacy of contraceptive methods: A review of the literature.Emerging female contraceptives.Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.The contraceptive vaginal ring, NuvaRing(®), a decade after its introduction.Contraception and headache.Vaginal health in contraceptive vaginal ring users - A review.Counseling on vaginal delivery of contraceptive hormones: implications for women's body knowledge and sexual health.Evaluating the efficacy and safety of a progestin- and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring.The therapeutic potential of vaginal drug delivery in the treatment of cervical cancer.Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis.Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections.Vaginal drug delivery for the localised treatment of cervical cancer.Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages.Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices.The optimization of an intravaginal ring releasing progesterone using a mathematical model.Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.Weight gain, body image and sexual function in young patients treated with contraceptive vaginal ring. A prospective pilot study.
P2860
Q24197649-98478E3F-9F04-4415-A1DB-6D3FA385D556Q24200949-1D15E58C-B7D8-40F9-9E6E-F7B82192CE9CQ24234337-389EFE9E-0D39-4043-A534-4BEE51F055A6Q24236702-C8A8B9FC-EC94-4F34-BD27-E3CCCA07E842Q24241209-3910687F-9BED-4365-815C-78DE8287C543Q24630988-B109BD82-695C-44DE-87BB-B370F81B448EQ26849373-5547078F-5C8D-4C4D-8AED-C8BA4B430144Q26861344-6C4138BB-5D9B-4827-8841-1B1D18E534A3Q33625073-0833BA9D-CB18-4BE6-94F4-CD56DCA3DEC7Q34110101-8F22D157-0D5E-489E-BDEA-51CDBA3F1B70Q34112217-C0C606D0-29D0-47C5-810E-5C6BF7051D4CQ34345741-AA1BE0D2-A6E8-4CE4-B919-1A983C32A48BQ34642459-1F38BEEE-98EF-4149-878C-949D513AF48AQ35599735-86338A21-DB88-4CEE-BCAA-140DE8FAC6F0Q36108786-9DF6D94A-42B7-477D-8016-648494727E90Q36711365-F92701DC-793C-4CF9-B019-F61FD4DB60DCQ36823561-60993581-621B-4208-A86E-8F7A301C1A3FQ36831198-433AA6E1-D14C-41B7-868A-E3D1634CA2D6Q36873346-3A1D26E4-EFDD-477F-8DA5-6B7ADB9C072AQ36904918-7FDCA049-9649-4871-BC2B-834096C452A8Q37098147-99B55CA5-D2F2-460E-92F5-4A857D9410DEQ37548016-157E9303-257A-4228-95F6-40024EEB1980Q37601287-A94F9776-02E9-4F3D-89A1-31909EB33671Q37688124-DA50C58B-A226-42E8-9397-B94055D92AE8Q37828533-8C1E9CA4-33F1-4DC0-AB75-29CBCDFC485BQ37990037-239D4AF4-7872-4FD6-BD9C-1B2B88E17851Q38056772-C784E4A5-9470-4E7A-BCD6-1EA60C62EDB2Q38083769-22B3B75C-1A35-4732-83D8-63AE4C2838A4Q38116095-0D29E658-0B0E-405B-B171-CC7CAC9E34FBQ38132846-C4BFF859-9D86-4D56-AC39-44ECA303D52AQ38238261-A8C0E7C5-7E89-4CDB-85A2-D526AE63DE03Q38498021-C4D9B22D-509E-4EDA-B247-51FE9299DE12Q38931213-5A1A435A-E130-4505-81BE-53AE884C314CQ39265131-B5747860-A709-4339-9A0C-27CF4A808A20Q39361267-94A1ADC7-891D-4427-A232-0C2E7E3B1C37Q42630326-F70BF89D-8294-4B29-B16F-CBEA0A6DCF0BQ45010869-E8DC0349-58A4-49C1-91B4-644ED54240EEQ45736420-181825CC-FE14-42E9-BBF8-E83359DE9BD8Q46503602-42B9BA06-77A4-44CB-A89A-AC7B46980CA5Q47220488-9C612FBF-FA98-467A-97EB-86DCB36AFFD1
P2860
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@en
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@nl
type
label
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@en
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@nl
prefLabel
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@en
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@nl
P2093
P1433
P1476
Efficacy, acceptability and to ...... diol and 3 mg of drospirenone.
@en
P2093
Birgit Karskov
Geert Page
Hans-Joachim Ahrendt
Ian Milsom
Israel Nisand
Johannes Bitzer
Maria Angeles Gómez
Wolfgang Urdl
P304
P356
10.1016/J.CONTRACEPTION.2006.07.004
P577
2006-09-27T00:00:00Z